You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CML, chronic myeloid leukemia, stop, niotinib, discontinue, imatinib, switch, MR4.5, undetectable, bcr-abl

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

CML, Chronic Myelogenous Leukemia, Leukemia, Myeloid Chronic Trial in Worldwide (Asciminib add-on, Imatinib, Nilotinib)

Recruiting
  • CML
  • +3 more
  • Asciminib add-on
  • +3 more
  • Augusta, Georgia
  • +46 more
Jan 23, 2023

Chronic Myeloid Leukemia Trial in Worldwide (nilotinib)

Active, not recruiting
Has Results
  • Chronic Myeloid Leukemia
  • Los Angeles, California
  • +61 more
Mar 17, 2022

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Trial in United States (Bosutinib, Dasatinib, Laboratory Biomarker

Active, not recruiting
  • Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • Anchorage, Alaska
  • +540 more
Dec 14, 2022

Chronyc Myeloid Leukemia Trial in Italy, Netherlands (Imatinib, Nilotinib)

Active, not recruiting
  • Chronyc Myeloid Leukemia
  • Alessandria, Italy
  • +81 more
Jan 4, 2022

Leukemia, Myelogenous, Chronic, BCR-ABL Positive Trial in France (Nilotinib)

Completed
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Angers, France
  • +9 more
Aug 17, 2022

Leukemia Trial in Worldwide (Dasatinib)

Active, not recruiting
Has Results
  • Leukemia
  • Birmingham, Alabama
  • +173 more
Dec 1, 2022

Chronic Phase Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia

Recruiting
  • Chronic Phase Chronic Myelogenous Leukemia
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 11, 2022

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Minimal Residual Disease Trial in United States (drug, other,

Recruiting
  • Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • Minimal Residual Disease
  • Goodyear, Arizona
  • +237 more
Jan 3, 2023

Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia Trial in Worldwide (Nilotinib)

Completed
Has Results
  • Chronic Myeloid Leukemia
  • Acute Lymphoblastic Leukemia
  • Bordeaux, Aquitaine, France
  • +11 more
Dec 6, 2020

CML, Chronic Phase Trial in Harbin (Flumatinib, Imatinib)

Not yet recruiting
  • CML, Chronic Phase
  • Harbin, Heilongjiang, China
    Institute of Hematology and Oncology, Harbin The First Hospital
May 5, 2022

Chronic Myeloid Leukemia (CML) Trial in France

Recruiting
  • Chronic Myeloid Leukemia (CML)
    • Annecy, France
    • +11 more
    Jul 18, 2023

    Asciminib RMP Study

    Not yet recruiting
    • Chronic Myeloid Leukemia
    • Asciminib
    • (no location specified)
    Jul 5, 2023

    BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib

    Active, not recruiting
    • Chronic Myeloid Leukemia
    • Dasatinib discontinuation
    • Rionero in Vulture, Potenza, Italy
    • +36 more
    Jan 4, 2022

    Chronic Myeloid Leukemia Trial in Germany (Nilotinib)

    Completed
    Has Results
    • Chronic Myeloid Leukemia
    • Mannheim, Baden-Wuerttemberg, Germany
    • +69 more
    Mar 21, 2022

    Effect of Pharmacogenetics on Imatinib Plasma Level and Response

    Active, not recruiting
    • Chronic Myeloid Leukemia
    • PCR
    • HPLC-UV
    • Assiut, Egypt
      South Egypt Cancer Institute
    Aug 6, 2022

    sCD62L and SPARC in Chronic Myeloid Leukemia Patients During

    Completed
    • Chronic Myeloid Leukemia
    • ELISA kit
    • Tanta, Egypt
      Tanta University
    May 18, 2022

    Myeloid Leukemia, Chronic Trial in Germany (dasatinib (SPRYCEL®))

    Active, not recruiting
    • Myeloid Leukemia, Chronic
    • dasatinib (SPRYCEL®)
    • Aachen, Germany
    • +52 more
    Jun 1, 2022

    Flumatinib, Chronic Myeloid Leukemia, Chronic Phase, Imatinib Trial in Shenzhen (Flumatinib)

    Recruiting
    • Flumatinib
    • +2 more
    • Shenzhen, Guangdong, China
      The Second People's Hospital of Shenzhen
    Mar 15, 2022

    Chronic Myelogenous Leukemia Trial in Canada, United States (Nilotinib)

    Completed
    Has Results
    • Chronic Myelogenous Leukemia
    • Fayetteville, Arkansas
    • +22 more
    Jun 29, 2021

    Chronic Myeloid Leukemia in Chronic Phase Trial in Shenzhen (Flumatinib, Dasatinib)

    Recruiting
    • Chronic Myeloid Leukemia in Chronic Phase
    • Shenzhen, Guangdong, China
      Shenzhen Second People's Hospital
    Jul 26, 2022

    BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase

    Active, not recruiting
    • Chronic Phase Philadelphia Positive
    • +2 more
      • Alessandria, Italy
      • +55 more
      Jan 4, 2022

      Chronic Myeloid Leukemia, Chronic Phase Trial in Spain (Ponatinib 15 MG, Acetylsalicylic acid 100 MG)

      Recruiting
      • Chronic Myeloid Leukemia, Chronic Phase
      • Ponatinib 15 MG
      • Acetylsalicylic acid 100 MG
      • L'Hospitalet De Llobregat, Barcelona, Spain
      • +12 more
      Feb 8, 2022

      Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission Trial (Asciminib, Imatinib)

      Not yet recruiting
      • Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission
      • (no location specified)
      Jun 7, 2022

      Chronic Myeloid Leukemia, Chronic Phase, Adult CML, Leukemia, Myeloid Trial in Augusta, Milwaukee (Asciminib, Ascimininb +

      Recruiting
      • Chronic Myeloid Leukemia, Chronic Phase
      • +3 more
      • Augusta, Georgia
      • +1 more
      Jul 14, 2022

      Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic

      Recruiting
      • Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
      • +2 more
      • Laboratory Biomarker Analysis
      • +2 more
      • Houston, Texas
        M D Anderson Cancer Center
      Jun 15, 2022